查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1595324

藥物安全檢測市場：按類型、臨床試驗、特徵和最終用戶分類 - 2025-2030 年全球預測

Pharmacovigilance Market by Type (Contract Outsourcing, In-house), Clinical Trial (Phase I, Phase II, Phase III), Function, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年藥物安全檢測市場價值為88.6億美元，預計到2024年將達到102.4億美元，複合年成長率為15.80%，到2030年將達到247.6億美元。

藥物安全檢測是與檢測、評估、理解和預防副作用和其他藥物相關問題相關的科學和活動。其範圍跨越整個藥物生命週期，需要強大的框架來確保病人安全和法規遵循。這包括臨床前和臨床試驗、上市後監測以及對藥品市場的主動監測，以盡量減少與藥品相關的風險。藥物安全檢測的使用對於醫療保健提供者、製藥公司和監管機構提供及時干預措施以減輕藥物不良反應 (ADR) 和提高藥物安全性至關重要。醫院、藥房和研究機構等最終使用部門嚴重依賴藥物安全檢測資料來為臨床實踐和政策決策提供資訊。慢性病盛行率的上升和藥物消費的增加正在推動藥物安全檢測市場的發展。此外，巨量資料分析、人工智慧和機器學習方面的技術進步是實現 ADR 即時資料處理和預測分析的關鍵成長要素。值得注意的機會包括數位醫療技術和遠端醫療的整合，這可以簡化資料收集和報告流程。市場挑戰包括藥物安全檢測系統的高成本、區域監管不一致以及整合不同資訊來源資料的複雜性。公司可以透過開發強大的訊號檢測系統和預測模型來增強 ADR 識別和分析來進行創新。此外，採用雲端基礎的解決方案可以提高資料可存取性和安全性，並建立更有效率的報告框架。隨著藥物安全檢測市場自我規範性質的發展，對個人化醫療和以患者為中心的方法的關注提供了重要的成長途徑。隨著藥物安全檢測繼續滿足市場的動態需求並為全球更安全的醫療保健做出貢獻，預測藥物安全性的生物標記和基因圖譜的研究也是一個有前途的創新領域。

主要市場統計
基準年[2023] 88.6億美元
預測年份 [2024] 102.4億美元
預測年份 [2030] 247.6億美元
複合年成長率（%） 15.80%

市場動態：揭示快速發展的藥物安全檢測市場的關鍵市場洞察

供需的動態交互作用正在改變藥物安全檢測市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 慢性病盛行率增加
    • 自願報告和電子健康記錄(EHR) 挖掘中藥物安全檢測應用的增加
    • 企業對外包服務的需求增加
    • 不良反應和藥物毒性發生率增加
  • 市場限制因素
    • 適合小型企業的高成本技術
  • 市場機會
    • COVID-19 的出現帶來了新的機遇
    • 醫療保健公司增加研發 (R&D) 投資
  • 市場挑戰
    • 缺乏技術純熟勞工

波特五力：駕馭藥物安全檢測市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解藥物安全檢測市場的外部影響

外部宏觀環境因素在塑造藥物安全檢測市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解藥物安全檢測市場的競爭格局

藥物安全檢測市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣藥物安全檢測市場供應商的績效評估

FPNV 定位矩陣是評估藥物安全檢測市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了藥物安全檢測市場的成功之路

藥物安全檢測市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病盛行率增加
      • 自發性通報和電子健康記錄 (EHR) 挖掘中藥物安全檢測應用的增加
      • 玩家對外包服務的需求增加
      • 不良反應和藥物毒性發生率增加
    • 抑制因素
      • 適合中小型企業的高成本技術
    • 機會
      • COVID-19 的出現帶來了新的機遇
      • 醫療保健公司增加研發 (R&D) 投資
    • 任務
      • 缺乏技術純熟勞工
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章藥物安全檢測市場：按類型

  • 合約外包
  • 公司內部

第7章 臨床試驗藥物安全檢測市場

  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段
  • 臨床前

第8章藥物安全檢測市場：按功能

  • 群組心臟事件記錄器
  • 電子病歷挖掘
  • 加強 ADR 報告
  • 自願報告
  • 有針對性的自願報告

第9章藥物安全檢測市場：依最終使用者分類

  • 學術研究所
  • 政府機構
  • 健康保險公司
  • 醫院和護理提供者
  • 製藥和生物技術公司

第10章美洲藥物安全檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區藥物安全檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲藥物安全檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Accenture, PLC
  • Bristol-Myers Squibb Company
  • Capgemini SE
  • ClinChoice
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • HCL Technologies Limited
  • ICON PLC
  • Infosys Limited
  • International Business Machines Corporation
  • IQVIA Inc.
  • ITclinical
  • Laboratory Corporation of America Holdings
  • Linical Co., Ltd.
  • Novartis AG
  • Oracle Corporation
  • Parexel International
  • Pfizer Inc.
  • Quanticate International limited
  • Sanofi SA
  • Syneos Health
  • TAKE Solutions Limited
  • TATA Consultancy Services Limited
  • Wipro Limited
Product Code: MRR-43676CF420A3

The Pharmacovigilance Market was valued at USD 8.86 billion in 2023, expected to reach USD 10.24 billion in 2024, and is projected to grow at a CAGR of 15.80%, to USD 24.76 billion by 2030.

Pharmacovigilance is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. Its scope extends across the entire drug lifecycle, necessitating a strong framework to ensure patient safety and regulatory compliance. This involves preclinical and clinical trials, post-marketing surveillance, and the active monitoring of the pharma market to minimize risks associated with pharmaceuticals. The application of pharmacovigilance is crucial for healthcare providers, pharmaceutical companies, and regulatory bodies, providing timely interventions to mitigate adverse drug reactions (ADRs) and enhance drug safety. End-use sectors, such as hospitals, pharmacies, and research institutions, heavily rely on pharmacovigilance data to inform clinical practices and policy decisions. The rising prevalence of chronic diseases and increased drug consumption propels the pharmacovigilance market. Furthermore, technological advancements in big data analytics, artificial intelligence, and machine learning are crucial growth factors, enabling real-time data processing and predictive analytics for ADRs. Notable opportunities include the integration of digital health technologies and telemedicine, which can streamline data gathering and reporting processes. Challenges in the market include the high cost of pharmacovigilance systems, regulatory discrepancies across regions, and the complex nature of data integration from diverse sources. Companies can innovate by developing robust signal detection systems and predictive models enhancing ADR identification and analysis. Additionally, embracing cloud-based solutions can improve data accessibility and security, fostering more efficient reporting frameworks. As the self-regulatory nature of the pharmacovigilance market evolves, focusing on personalized medicine and patient-centric approaches offers vital paths for growth. Research into biomarkers and genetic profiles to predict drug safety is another promising area of innovation, ensuring that pharmacovigilance continues to meet the dynamic needs of the market and contributes to safer healthcare outcomes globally.

KEY MARKET STATISTICS
Base Year [2023] USD 8.86 billion
Estimated Year [2024] USD 10.24 billion
Forecast Year [2030] USD 24.76 billion
CAGR (%) 15.80%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pharmacovigilance Market

The Pharmacovigilance Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increase in the Prevalence of Chronic Diseases
    • Rise in Pharmacovigilance Applications in Spontaneous Reporting and Electronic Health Record (EHR) Mining
    • Rise in Demand for Outsourcing Services by Players
    • Rising Incidence of ADR and Drug Toxicity
  • Market Restraints
    • High-cost Technology for Small and Mid-sized Players
  • Market Opportunities
    • Emergence of COVID-19 have Opened New Opportunities
    • Rising Investment in Research and Development (R&D) by Healthcare Companies
  • Market Challenges
    • Lack of Skilled Labor

Porter's Five Forces: A Strategic Tool for Navigating the Pharmacovigilance Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pharmacovigilance Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pharmacovigilance Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pharmacovigilance Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pharmacovigilance Market

A detailed market share analysis in the Pharmacovigilance Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pharmacovigilance Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pharmacovigilance Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pharmacovigilance Market

A strategic analysis of the Pharmacovigilance Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pharmacovigilance Market, highlighting leading vendors and their innovative profiles. These include Accenture, PLC, Bristol-Myers Squibb Company, Capgemini SE, ClinChoice, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, HCL Technologies Limited, ICON PLC, Infosys Limited, International Business Machines Corporation, IQVIA Inc., ITclinical, Laboratory Corporation of America Holdings, Linical Co., Ltd., Novartis AG, Oracle Corporation, Parexel International, Pfizer Inc., Quanticate International limited, Sanofi S.A., Syneos Health, TAKE Solutions Limited, TATA Consultancy Services Limited, and Wipro Limited.

Market Segmentation & Coverage

This research report categorizes the Pharmacovigilance Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Contract Outsourcing and In-house.
  • Based on Clinical Trial, market is studied across Phase I, Phase II, Phase III, Phase IV, and Pre-Clinical.
  • Based on Function, market is studied across Cohort Event Monitoring, EHR Mining, Intensified ADR Reporting, Spontaneous Reporting, and Targeted Spontaneous Reporting.
  • Based on End-User, market is studied across Academic & Research Institutes, Government Agencies, Health Insurance Companies, Hospitals & Care Providers, and Pharma & Biotech Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in the Prevalence of Chronic Diseases
      • 5.1.1.2. Rise in Pharmacovigilance Applications in Spontaneous Reporting and Electronic Health Record (EHR) Mining
      • 5.1.1.3. Rise in Demand for Outsourcing Services by Players
      • 5.1.1.4. Rising Incidence of ADR and Drug Toxicity
    • 5.1.2. Restraints
      • 5.1.2.1. High-cost Technology for Small and Mid-sized Players
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of COVID-19 have Opened New Opportunities
      • 5.1.3.2. Rising Investment in Research and Development (R&D) by Healthcare Companies
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of Skilled Labor
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pharmacovigilance Market, by Type

  • 6.1. Introduction
  • 6.2. Contract Outsourcing
  • 6.3. In-house

7. Pharmacovigilance Market, by Clinical Trial

  • 7.1. Introduction
  • 7.2. Phase I
  • 7.3. Phase II
  • 7.4. Phase III
  • 7.5. Phase IV
  • 7.6. Pre-Clinical

8. Pharmacovigilance Market, by Function

  • 8.1. Introduction
  • 8.2. Cohort Event Monitoring
  • 8.3. EHR Mining
  • 8.4. Intensified ADR Reporting
  • 8.5. Spontaneous Reporting
  • 8.6. Targeted Spontaneous Reporting

9. Pharmacovigilance Market, by End-User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutes
  • 9.3. Government Agencies
  • 9.4. Health Insurance Companies
  • 9.5. Hospitals & Care Providers
  • 9.6. Pharma & Biotech Companies

10. Americas Pharmacovigilance Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pharmacovigilance Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pharmacovigilance Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Accenture, PLC
  • 2. Bristol-Myers Squibb Company
  • 3. Capgemini SE
  • 4. ClinChoice
  • 5. F. Hoffmann-La Roche AG
  • 6. GlaxoSmithKline PLC
  • 7. HCL Technologies Limited
  • 8. ICON PLC
  • 9. Infosys Limited
  • 10. International Business Machines Corporation
  • 11. IQVIA Inc.
  • 12. ITclinical
  • 13. Laboratory Corporation of America Holdings
  • 14. Linical Co., Ltd.
  • 15. Novartis AG
  • 16. Oracle Corporation
  • 17. Parexel International
  • 18. Pfizer Inc.
  • 19. Quanticate International limited
  • 20. Sanofi S.A.
  • 21. Syneos Health
  • 22. TAKE Solutions Limited
  • 23. TATA Consultancy Services Limited
  • 24. Wipro Limited

LIST OF FIGURES

  • FIGURE 1. PHARMACOVIGILANCE MARKET RESEARCH PROCESS
  • FIGURE 2. PHARMACOVIGILANCE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PHARMACOVIGILANCE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PHARMACOVIGILANCE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PHARMACOVIGILANCE MARKET DYNAMICS
  • TABLE 7. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CONTRACT OUTSOURCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PRE-CLINICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY COHORT EVENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY EHR MINING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY INTENSIFIED ADR REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY TARGETED SPONTANEOUS REPORTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY HEALTH INSURANCE COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY HOSPITALS & CARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL PHARMACOVIGILANCE MARKET SIZE, BY PHARMA & BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES PHARMACOVIGILANCE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CHINA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. INDIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA PHARMACOVIGILANCE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. ITALY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. POLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. QATAR PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY CLINICAL TRIAL, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM PHARMACOVIGILANCE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 196. PHARMACOVIGILANCE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 197. PHARMACOVIGILANCE MARKET, FPNV POSITIONING MATRIX, 2023